Cargando…

Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer

OBJECTIVE: To develop and evaluate the screening performance of a low-cost high-risk screening strategy for breast cancer in low resource areas. METHODS: Based on the Multi-modality Independent Screening Trial, 6 questionnaire-based risk factors of breast cancer (age at menarche, age at menopause, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yubei, Wang, Huan, Lyu, Zhangyan, Dai, Hongji, Liu, Peifang, Zhu, Ying, Song, Fengju, Chen, Kexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500221/
https://www.ncbi.nlm.nih.gov/pubmed/34570443
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0758
_version_ 1784795169219936256
author Huang, Yubei
Wang, Huan
Lyu, Zhangyan
Dai, Hongji
Liu, Peifang
Zhu, Ying
Song, Fengju
Chen, Kexin
author_facet Huang, Yubei
Wang, Huan
Lyu, Zhangyan
Dai, Hongji
Liu, Peifang
Zhu, Ying
Song, Fengju
Chen, Kexin
author_sort Huang, Yubei
collection PubMed
description OBJECTIVE: To develop and evaluate the screening performance of a low-cost high-risk screening strategy for breast cancer in low resource areas. METHODS: Based on the Multi-modality Independent Screening Trial, 6 questionnaire-based risk factors of breast cancer (age at menarche, age at menopause, age at first live birth, oral contraceptive, obesity, family history of breast cancer) were used to determine the women with high risk of breast cancer. The screening performance of clinical breast examination (CBE), breast ultrasonography (BUS), and mammography (MAM) were calculated and compared to determine the optimal screening method for these high risk women. RESULTS: A total of 94 breast cancers were detected among 31,720 asymptomatic Chinese women aged 45–65 years. Due to significantly higher detection rates (DRs) and suitable coverage of the population, high risk women were defined as those with any of 6 risk factors. Among high risk women, the DR for BUS [3.09/1,000 (33/10,694)] was similar to that for MAM [3.18/1,000 (34/10,696)], while it was significantly higher than that for the CBE [1.73/1,000 (19/10,959), P = 0.002]. Compared with MAM, BUS showed significantly higher specificity [98.64% (10,501/10,646) vs. 98.06% (10,443/10,650), P = 0.001], but no significant differences in sensitivity [68.75% (33/48) vs. 73.91% (34/46)], positive prediction values [18.54% (33/178) vs. 14.11% (34/241)], and negative prediction values [99.86% (10,501/10,516) vs. 99.89% (10,443/10,455)]. Further analyses showed no significant difference in the percentages of early stage breast cancer [53.57% (15/28) vs. 50.00% (15/30)], lymph node involvement [22.73% (5/22) vs. 28.00% (7/25)], and tumor size ≥ 2 cm [37.04% (10/27) vs. 29.03% (9/31)] between BUS and MAM. Subgroup analyses stratified by breast densities or age at enrollment showed similar results. CONCLUSIONS: The low-cost high-risk screening strategy based on 6 questionnaire-based risk factors was an easy-to-use method to identify women with high risk of breast cancer. Moreover, BUS and MAM had comparable screening performances among high risk women.
format Online
Article
Text
id pubmed-9500221
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Compuscript
record_format MEDLINE/PubMed
spelling pubmed-95002212022-10-21 Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer Huang, Yubei Wang, Huan Lyu, Zhangyan Dai, Hongji Liu, Peifang Zhu, Ying Song, Fengju Chen, Kexin Cancer Biol Med Original Article OBJECTIVE: To develop and evaluate the screening performance of a low-cost high-risk screening strategy for breast cancer in low resource areas. METHODS: Based on the Multi-modality Independent Screening Trial, 6 questionnaire-based risk factors of breast cancer (age at menarche, age at menopause, age at first live birth, oral contraceptive, obesity, family history of breast cancer) were used to determine the women with high risk of breast cancer. The screening performance of clinical breast examination (CBE), breast ultrasonography (BUS), and mammography (MAM) were calculated and compared to determine the optimal screening method for these high risk women. RESULTS: A total of 94 breast cancers were detected among 31,720 asymptomatic Chinese women aged 45–65 years. Due to significantly higher detection rates (DRs) and suitable coverage of the population, high risk women were defined as those with any of 6 risk factors. Among high risk women, the DR for BUS [3.09/1,000 (33/10,694)] was similar to that for MAM [3.18/1,000 (34/10,696)], while it was significantly higher than that for the CBE [1.73/1,000 (19/10,959), P = 0.002]. Compared with MAM, BUS showed significantly higher specificity [98.64% (10,501/10,646) vs. 98.06% (10,443/10,650), P = 0.001], but no significant differences in sensitivity [68.75% (33/48) vs. 73.91% (34/46)], positive prediction values [18.54% (33/178) vs. 14.11% (34/241)], and negative prediction values [99.86% (10,501/10,516) vs. 99.89% (10,443/10,455)]. Further analyses showed no significant difference in the percentages of early stage breast cancer [53.57% (15/28) vs. 50.00% (15/30)], lymph node involvement [22.73% (5/22) vs. 28.00% (7/25)], and tumor size ≥ 2 cm [37.04% (10/27) vs. 29.03% (9/31)] between BUS and MAM. Subgroup analyses stratified by breast densities or age at enrollment showed similar results. CONCLUSIONS: The low-cost high-risk screening strategy based on 6 questionnaire-based risk factors was an easy-to-use method to identify women with high risk of breast cancer. Moreover, BUS and MAM had comparable screening performances among high risk women. Compuscript 2022-09-15 2021-09-28 /pmc/articles/PMC9500221/ /pubmed/34570443 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0758 Text en Copyright: © 2022, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Article
Huang, Yubei
Wang, Huan
Lyu, Zhangyan
Dai, Hongji
Liu, Peifang
Zhu, Ying
Song, Fengju
Chen, Kexin
Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
title Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
title_full Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
title_fullStr Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
title_full_unstemmed Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
title_short Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
title_sort development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500221/
https://www.ncbi.nlm.nih.gov/pubmed/34570443
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0758
work_keys_str_mv AT huangyubei developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer
AT wanghuan developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer
AT lyuzhangyan developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer
AT daihongji developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer
AT liupeifang developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer
AT zhuying developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer
AT songfengju developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer
AT chenkexin developmentandevaluationofthescreeningperformanceofalowcosthighriskscreeningstrategyforbreastcancer